Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Vx 001 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms VaxLung
- Sponsors Vaxon Biotech
- 23 Jun 2017 This trial has been discontinued in Greece (end date: 5 Mar 2017).
- 01 Jun 2017 According to a Vaxon biotech media release, results will be presented at at the ESMO.
- 01 Jun 2017 Status changed from active, no longer recruiting to completed, according to a Vaxon Biotech Media Release.